David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
The RMR Group
RMR
$336M
| $297K | ﹤0.01% |
4,868
-2,214
| -31% | -$146K |
|
|
AKS
3177
PUT
DELISTED
AK Steel Holding Corp
AKS
| $297K | ﹤0.01% |
108,100
+8,100
| +8% | +$23K |
|
|
NBRV
3178
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $296K | ﹤0.01% |
+485
| New | +$265K |
|
3179
WEX
WEX
$6.81B
| $295K | ﹤0.01% |
1,536
-84,768
| -98% | -$14.3M |
|
3180
American International
AIG
$39.9B
| $294K | ﹤0.01% |
6,830
-195,564
| -97% | -$8.36M |
|
3181
Globalstar
GSAT
$10.6B
| $294K | ﹤0.01% |
45,603
-222,230
| -83% | -$1.89M |
|
3182
CALL
Lumentum
LITE
$79.4B
| $294K | ﹤0.01% |
+5,200
| New | +$249K |
|
|
CY
3183
DELISTED
Cypress Semiconductor
CY
| $294K | ﹤0.01% |
+19,720
| New | +$286K |
|
|
MITT
3184
TPG Mortgage Investment Trust
MITT
$214M
| $292K | ﹤0.01% |
5,776
-23,989
| -81% | -$1.26M |
|
3185
CALL
Insmed
INSM
$27.1B
| $291K | ﹤0.01% |
10,000
| – | – |
|
|
TLGT
3186
DELISTED
Teligent, Inc
TLGT
| $291K | ﹤0.01% |
25,116
+4,743
| +23% | +$71.5K |
|
3187
Baker Hughes
BKR
$61.4B
| $290K | ﹤0.01% |
10,450
-6,635
| -39% | -$168K |
|
3188
Comstock Resources
CRK
$4.16B
| $289K | ﹤0.01% |
+41,771
| New | +$275K |
|
3189
Fox Factory Holding Corp
FOXF
$892M
| $289K | ﹤0.01% |
4,135
-12,103
| -75% | -$768K |
|
3190
FreightCar America
RAIL
$238M
| $289K | ﹤0.01% |
47,051
+15,738
| +50% | +$116K |
|
3191
NACCO Industries
NC
$313M
| $288K | ﹤0.01% |
7,531
+100
| +1% | +$3.65K |
|
3192
PDS Biotechnology
PDSB
$12.4M
| $288K | ﹤0.01% |
38,934
+1,746
| +5% | +$14.6K |
|
|
CTT
3193
DELISTED
CATCHMARK TIMBER TRUST, INC.
CTT
| $286K | ﹤0.01% |
29,077
-143,434
| -83% | -$1.31M |
|
3194
CALL
Applied Industrial Technologies
AIT
$12.3B
| $285K | ﹤0.01% |
+4,800
| New | +$278K |
|
3195
Align Technology
ALGN
$11.3B
| $284K | ﹤0.01% |
1,000
-9,707
| -91% | -$2.32M |
|
3196
CONMED
CNMD
$1.53B
| $284K | ﹤0.01% |
3,412
-21,791
| -86% | -$1.58M |
|
3197
CALL
Agnico Eagle Mines
AEM
$113B
| $283K | ﹤0.01% |
6,500
-7,800
| -55% | -$330K |
|
3198
CALL
Core Laboratories
CLB
$553M
| $283K | ﹤0.01% |
4,100
-8,300
| -67% | -$556K |
|
3199
China Yuchai International
CYD
$1.48B
| $283K | ﹤0.01% |
17,848
-10,277
| -37% | -$166K |
|
3200
Lifecore Biomedical
LFCR
$176M
| $283K | ﹤0.01% |
23,068
+12,648
| +121% | +$154K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.